Lucid Capital initiated coverage of CalciMedica (CALC) with a Buy rating and $13 price target The company’s lead candidate, Auxora, is a potent and selective intravenous CRAC channel inhibitor in development for multiple acute inflammatory conditions, the analyst tells investors in a research note. The firm says recent results highlight Auxora’s potential in addressing acute inflammatory conditions with large unmet needs and sizable patient populations.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.